• Successful initial public offering (“IPO”), and admission to the premium listing segment of the Official List of the UK Listing Authority and to trading on the Main Market of the London Stock Exchange (“LSE”), with gross proceeds of $156 million (which includes over-allotment option closed post-period-end) to fuel growth of our 20 existing businesses and further company expansion, increasing from 18 to 20 businesses following the IPO
• Continued strong progress in funding, research and development across a number of subsidiaries
• Added five new partners to our extensive network of 33 U.S. universities and 32 U.S. Federal government laboratories to expand our potential new deal pipeline
• Hired additional key senior leadership, including the first General Counsel of the Group, the former outside counsel who led the U.S. legal preparation of our IPO, and a new CEO at our ProGDerm subsidiary, a seasoned executive with more than 30 years’ experience in healthcare and biologics
• Post-period-end, Allied Minds created two new businesses: (i) Allied-Bristol Life Sciences, LLC, in collaboration with Bristol-Myers Squibb and (ii) Whitewood Encryption Systems, Inc.; and achieved a significant technical milestone in our subsidiary Spin Transfer Technologies
For full access, please click here.
Help employers find you! Check out all the jobs and post your resume.
